NEON THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • June 15th, 2018 • Neon Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
The undersigned understands that Morgan Stanley & Co. LLC (“Morgan Stanley”) and Merrill Lynch, Pierce, Fenner & Smith Incorporated (“Merrill Lynch”) propose to enter into an Underwriting Agreement (the “Underwriting Agreement”) with Neon Therapeutics, Inc., a Delaware corporation (the “Company”), providing for the public offering (the “Public Offering”) by the several Underwriters, including Morgan Stanley and Merrill Lynch (the “Underwriters”), of shares of common stock (the “Shares”), par value $0.001 per share, of the Company (the “Common Stock”).
NEON THERAPEUTICS, INC. [FORM OF] OFFICER INDEMNIFICATION AGREEMENTIndemnification Agreement • June 15th, 2018 • Neon Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”) is made as of [ ] by and between Neon Therapeutics, Inc., a Delaware corporation (the “Company”), and [Officer] (“Indemnitee”).(1)
EMPLOYMENT AGREEMENTEmployment Agreement • June 15th, 2018 • Neon Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made by and between Neon Therapeutics, Inc., a Delaware corporation (the “Company”), and (the “Executive”), and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”).
